Page 157 - rcv31n3.vp

Revista Uruguaya de Cardiología Prevención cardiovascular en el diabético
Volumen 31 | nº 3 | Diciembre 2016 Washington Vignolo, Bernardo Layerle

56. Weber MA, Bakris GL, Jamerson K, Weir M, Engl J Med. 2001 Sep 20;345(12):851-60.
Kjeldsen SE, Devereux RB, et al. Cardiovascular doi:10.1056/NEJMoa011303.
events during differing hypertension therapies in pa-
66. Atkins RC, Briganti EM, Lewis JB, Hunsicker
tients with diabetes. J Am Coll Cardiol. 2010 Jun
LG, Braden G, Champion de Crespigny PJ, et
29;56(1):77-85. doi:10.1016/j.jacc.2010.02.046.
al. Proteinuria reduction and progression to renal
57. Patel A, ADVANCE Collaborative Group. failure in patients with type 2 diabetes mellitus and
Effects of a fixed combination of perindopril and in- overt nephropathy. Am J Kidney Dis. 2005 Feb [cita-
dapamide on macrovascular and microvascular out- do 2016 Jun 6];45(2):281-7. Disponible en:
comes in patients with type 2 diabetes mellitus (the http://www.ncbi.nlm.nih.gov/pubmed/15685505.
ADVANCE trial): a randomised controlled trial. Lan-
67. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Po-
cet. 2007 Sep 8;370(9590):829-40.
rush JG, Rouleau JL, et al. Impact of achieved blood
doi:10.1016/S0140-6736(07)61303-8.
pressure on cardiovascular outcomes in the irbesartan
58. Blood Pressure Lowering Treatment Trialists’ diabetic nephropathy trial. J Am Soc Nephrol. 2005 Jul
Collaboration. Effects of different blood pressure-lo- 1;16(7):2170-9. doi:10.1681/ASN.2004090763.
wering regimens on major cardiovascular events in in- 68. Pohl MA, Blumenthal S, Cordonnier DJ, De
dividuals with and without diabetes mellitus: results of Alvaro F, De Ferrari G, Eisner G, et al. Indepen-
prospectively designed overviews of randomized trials. dent and additive impact of blood pressure control and
Arch Intern Med. 2005 Jun 27;165(12):1410-19. angiotensin II receptor blockade on renal outcomes in
doi:10.1001/archinte.165.12.1410. the irbesartan diabetic nephropathy trial: clinical im-
plications and limitations. J Am Soc Nephrol. 2005 Aug
59. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid
24;16(10):3027-37. doi:10.1681/ASN.2004110919.
D, Rachmani R. Use of enalapril to attenuate decli-
ne in renal function in normotensive, normoalbumi- 69. Brenner BM, Cooper ME, de Zeeuw D, Keane WF,
nuric patients with type 2 diabetes mellitus. A rando- Mitch WE, Parving HH, et al. Effects of losartan on
mized, controlled trial. Ann Intern Med. 1998 Jun 15 renal and cardiovascular outcomes in patients with type
[citado 2016 Jun 3];128(12 Pt 1):982-8. Disponible 2 diabetes and nephropathy. N Engl J Med. 2001 Sep
en: http://www.ncbi.nlm.nih.gov/pubmed/9625684. 20;345(12):861-9. doi:10.1056/NEJMoa011161.
60. Bilous R, Chaturvedi N, Sjølie AK, Fuller J, 70. Casas JP, Chua W, Loukogeorgakis S, Vallance
Klein R, Orchard T, et al. Effect of candesartan on P, Smeeth L, Hingorani AD, et al. Effect of inhi-
microalbuminuria and albumin excretion rate in dia- bitors of the renin-angiotensin system and other an-
betes: three randomized trials. Ann Intern Med. 2009 tihypertensive drugs on renal outcomes: systematic
Jul 7 [2016 Jun 3];151(1):11-20. Disponible en: review and meta-analysis. Lancet. 2005 Dec
http://www.ncbi.nlm.nih.gov/pubmed/19451554. 10;366(9502):2026-33.
doi:10.1016/S0140-6736(05)67814-2.
61. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev
IP, Brusegan V, et al. Preventing microalbuminu- 71. Effects of ramipril on cardiovascular and microvas-
ria in type 2 diabetes. N Engl J Med. 2004 Nov cular outcomes in people with diabetes mellitus: re-
4;351(19):1941-51. doi:10.1056/NEJMoa042167. sults of the HOPE study and MICRO-HOPE sub-
study. Heart Outcomes Prevention Evaluation Study
62. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Ka-
Investigators. Lancet. 2000 Jan 22 [citado 2016 Abr
tayama S, Menne J, et al. Olmesartan for the de-
27];355(9200):253-9. Disponible en: http://www.
lay or prevention of microalbuminuria in type 2 dia-
ncbi.nlm.nih.gov/pubmed/10675071.
betes. N Engl J Med. 2011 Mar 10;364(10):907-17.
doi:10.1056/NEJMoa1007994. 72. The Heart Outcomes Prevention Evaluation
Study Investigators. Effects of an angiotensin-con-
63. Parving HH, Lehnert H, Bröchner-Mortensen verting-enzyme inhibitor, ramipril, on cardiovascular
J, et al. The effect of irbesartan on the development events in high-risk patients. N Engl J Med. 2000 Jan
of diabetic nephropathy in patients with type 2 diabe- 20;342(3):145-53.
tes. N Engl J Med. 2001 Sep 20;345(12):870-8. doi:10.1056/NEJM200001203420301.
doi:10.1056/NEJMoa011489.
73. Svensson P, de Faire U, Sleight P, Yusuf S,
64. Barnett AH, Bain SC, Bouter P, Karlberg B, Ostergren J. Comparative effects of ramipril on
Madsbad S, Jervell J, et al. Angiotensin-receptor ambulatory and office blood pressures: a HOPE
blockade versus converting-enzyme inhibition in type 2 Substudy. Hypertension. 2001 Dec 1[citado2016 Set
diabetes and nephropathy. N Engl J Med. 2004 Nov 30];38(6):E28-32. Disponible en: http://www.ncbi.
4;351(19):1952-61. doi:10.1056/NEJMoa042274. nlm.nih.gov/pubmed/11751742.
65. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, 74. Marre M, Lievre M, Chatellier G, Mann JFE,
Pohl MA, Lewis JB, et al. Renoprotective effect of Passa P, Ménard J, et al; DIABHYCAR Study
the angiotensin-receptor antagonist irbesartan in Investigators. Effects of low dose ramipril on car-
patients with nephropathy due to type 2 diabetes. N diovascular and renal outcomes in patients with type
501